Annual Report

See All

Application note

See All

Our new study highlights the development and validation of trastuzumab specific anti-idiotypic Affimer binders within a pharmacokinetic assay.

In a new study we have applied Affimer technology to improve the specificity and sensitivity of a key diagnostic assay for the multi-antibiotic resistant Clostridium difficile.

Affmer proteins are recombinant affinity reagents that exhibit high affinity and high specificity binding across a range of reaction conditions.

General Meetings

See All

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier

Notice of the annual general meeting of the Company to be held at the officces of FTI Consulting at 200 Aldersgate, Aldersgate Street, London EC1A 4HD on Friday 20 January 2017 at 10.00 a.m. 

Interim Announcements

See All

Investor info

See All

This 2 page document contains a company overview, details of Avacta's strategy and information on the investment proposition. It also contains some key informaiton on financials, the management team and key contacts. 

An analysis of Avacta's unaudited preliminary results for the year ending 31 July 2017 by Turner Pope. 

An analysis of Avacta's unaudited preliminary results for the year ending 31 July 2017 by Capital Network. 


See All

Poster producrd by Amy Reeves, Covance Laboratories Ltd, Harrogate, UK about how they used Affimer technology for detecting and quantifying the breast cancer drug Trastuzumab. 

This poster demonstrates that we have demonstrated the proof-of-principle that the serum half-life of Affimer proteins can be significantly increased by binding to albumin in mice and the resulting in vivo half-life extension of the Affimer proteins is similar to other scaffold technologies.

Preliminary Announcement

See All

Please note: This file is an audio / video webcast and requires the WebEx ARF player to playback the recording. Download ARF player here. 

Preliminary Results for the Year Ended 31 July 2015.


See All

Presentation given by Avacta CEO Alastair Smith in February 2018, providing  a review of progress against the objectives set in 2015 that were outlined at its Capital Markets Day, which took place on 7 February 2018 for financial analysts and institutional investors.

Presentation given by Avacta Chief Executive Officer Dr Alastair Smith. 

Presentation given by Avacta's Chief Technology Officer Dr Matt Johnson in October 2017. 

Published Paper

See All

Mass spectrometry‐based proteomics identifies putative substrates of the ubiquitin‐dependent remodeler VCP in human cells and reveals its role in the regulation of the c‐Myc level and activity.

A novel Affimer-functionalised interdigitated electrode-based capacitive biosensor platform was developed for detection and estimation of Her4, a protein tumour biomarker, in undiluted serum.

This review examines the potential of scaffold-based binding proteins to fulfil these requirements.

Research Note

See All


See All

In this free webinar, scientists from leading CRO, Covance, validated the use of Affimer reagents as critical assay reagents in a regulated pharmacokinetic assay.

This webinar features a presentation by Avacta Life Sciences' Chief Technology Officer Dr Matt Johnson. In it, he discusses using Affimer technology to inhibit PD-L1, an immune check point protein expressed by tumor cells to trick t-cells into not destroying them.

White paper

See All

New white paper examines a range of alternatives to antibodies This paper reviews the main applications of affnity binders and the requirements placed on them according to application.

This case study outlines Affimer technology for the generation of cancer immune checkpoint inhibitors, to demonstrate the rapid identification of a number of biotherapeutic candidate molecules.

A case study looking at the findings of a published study  on the HIF-1α/p300 protein–protein interaction, which  plays a key role in tumor metabolism and thus represents a high value target for anticancer drug-development.